Pfizer, BioNTech begin omicron-specific COVID-19 vaccine study
Posted on AllSides January 25th, 2022
From The Right
COVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that they would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.
The companies said there would be three trials examining different regimens of the current Pfizer-BioNTech vaccine for an omicron-based vaccine.
The study will also draw upon some participants from the companies’ Phase 3 COVID-19 booster study, evaluating up to 1,420 people.
The first cohort received two doses of the Pfizer-BioNTech vaccine 90-180 days before enrollment and will receive one or two doses of the omicron-based vaccine.
In the second, participants received three doses...